A detailed history of Farallon Capital Management LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Farallon Capital Management LLC holds 4,000 shares of BPMC stock, worth $361,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,000
Previous 4,000 -0.0%
Holding current value
$361,840
Previous $431,000 14.39%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $175,840 - $371,360
4,000 New
4,000 $368,000
Q3 2023

Nov 14, 2023

BUY
$46.9 - $66.0 $187,600 - $264,000
4,000 New
4,000 $200,000
Q1 2023

May 15, 2023

SELL
$37.97 - $50.0 $2.72 Million - $3.58 Million
-71,580 Reduced 76.15%
22,420 $1.01 Million
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $3.86 Million - $6.25 Million
94,000 New
94,000 $4.12 Million
Q2 2022

Aug 15, 2022

SELL
$45.23 - $70.15 $6.56 Million - $10.2 Million
-145,000 Reduced 10.69%
1,211,987 $61.2 Million
Q1 2022

May 16, 2022

BUY
$54.1 - $110.08 $29.5 Million - $60 Million
545,240 Added 67.17%
1,356,987 $86.7 Million
Q4 2021

Feb 14, 2022

SELL
$94.25 - $115.99 $12.5 Million - $15.4 Million
-132,656 Reduced 14.05%
811,747 $86.9 Million
Q3 2021

Nov 15, 2021

SELL
$80.98 - $109.47 $14.6 Million - $19.8 Million
-180,597 Reduced 16.05%
944,403 $97.1 Million
Q2 2021

Aug 13, 2021

BUY
$82.78 - $101.0 $35.6 Million - $43.5 Million
430,209 Added 61.92%
1,125,000 $99 Million
Q1 2021

May 17, 2021

BUY
$90.71 - $108.28 $63 Million - $75.2 Million
694,791 New
694,791 $67.6 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Farallon Capital Management LLC Portfolio

Follow Farallon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.